Evidence map›Paper›PMID 40121346›Full record

ArticleInsights into imaging2025

Using optimized CT type to predict histological classifications of thymic epithelial tumors: a radiomics integrated analysis.

Zhengping Zhang, Kede Mi, Zhaojun Wang, Xiaoyan Yang, Shuping Meng, Xingcang Tian, Yanzhu Han, Yuling Qu, Li Zhu, Juan Chen

Abstract read
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhengping Zhang *Department of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China.
Kede Mi *Department of Medical, General Hospital of Ningxia Medical University, Yinchuan, China.
Zhaojun Wang *Department of Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, China.
Xiaoyan Yang *Department of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China.
Shuping MengDepartment of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Xingcang TianDepartment of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Yanzhu HanDepartment of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Yuling QuDepartment of Pathology, General Hospital of Ningxia Medical University, Yinchuan, China.
Li ZhuDepartment of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Juan ChenDepartment of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China. chenjuan7419@163.com.ORCID http://orcid.org/0000-0001-5801-9124

Funding

Natural Science Foundation of Ningxia Province 2022AAC03581
6 · The paper itself

Abstract

objectiveTo develop and externally validate an integrated model that utilizes optimized radiomics features from non-contrast-enhanced CT (NE-CT) or contrast-enhanced CT (CE-CT), along with morphological features and clinical risk factors, to predict histological classifications of thymic epithelial tumors (TETs).

methodsA total of 182 patients with TET, classified as the low-risk group and the high-risk group based on histology, were divided into a training cohort (N = 122, center 1) and an external validation cohort (N = 60, center 2). Radiomics features were extracted from different CT types, followed by feature selection, including consistency, correlation, and importance tests, to generate Rad-scores for both NE-CT and CE-CT. The integrated model was developed by combining the optimal Rad-score, morphological features, and clinical risk factors using multivariate logistic regression. Model performance was assessed by the area under the receiver operating characteristic curve (AUC) and compared by Delong test. A nomogram was used to visually present the integrated model.

resultsA total of 851 radiomics features were extracted, with NE-CT and CE-CT Rad-scores consisting of four and five features, respectively. The AUCs of the CE-CT Rad-score were higher than those of the NE-CT Rad-score in both the training cohort (0.783 vs 0.749) and the external validation cohort (0.775 vs 0.723, p = 0.361). The integrated model, combining five morphological features and the CE-CT Rad-score, achieved AUCs of 0.814 and 0.802 in the training and external validation cohorts, respectively.

conclusionThe integrated model, incorporating radiomics features from CE-CT and morphological features, can help to identify the histological classifications of TETs. CRITICAL RELEVANCE STATEMENT: This study developed an integrated model based on radiomics features from contrast-enhanced CT and morphological features, demonstrating that the integrated model has impressive predictive capability in distinguishing histological classifications of thymic epithelial tumors through external validation. KEY POINTS: Radiomics features extracted from CT more effectively represented thymic epithelial tumor (TET) heterogeneity than morphological features. The radiomics model using contrast-enhanced CT outperformed that using non-contrast-enhanced CT in identifying histological classifications of TET. The integrated model, combining radiomics and morphological features, exhibited the highest performance in predicting TET histological classifications.

Indexed as

Computed tomographyRadiomicsThymic epithelial tumors

Identifiers

PMID40121346
PMCPMC11929666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.